

WuXi NextCODE expands laboratory footprint into the U.S.

01 April 2019 | News | By Manbeena Chawla

WuXi NextCODE launches new state-of-the-art genetic analysis laboratory in U.S. with Illumina's New TruSight500™ Assay



WuXi NextCODE, a global genomic data and insights company, is expanding its laboratory footprint into the U.S. with the opening of a state-of-the-art, CLIA-certified and CAP-accredited genetic analysis laboratory in Woburn, Massachusetts. The new laboratory is geographically close to WuXi NextCODE's U.S. office in Cambridge, Massachusetts.

As the first CAP/CLIA/ISO 15189 certified laboratory in China, the company's Shanghai laboratory already offers comprehensive next generation sequencing (NGS) clinical and discovery research services. WuXi NextCODE has also recently acquired a large scale NGS laboratory in Dublin, Ireland, which is already CAP-accredited and anticipated to be CLIA-certified in the third quarter of 2019.

The first oncology panel to be offered in the U.S. lab's CLIA/CAP environment will be Illumina's new TruSight Oncology 500™ (TSO 500), which is a comprehensive pan-cancer tumor profiling assay that can support prospective patient enrollment in clinical trials, retrospective exploratory translational research and biomarker discovery applications. The TSO 500 research use only (RUO) test provides comprehensive coverage of established and emerging oncology biomarkers with the ability to provide rapid turnaround time. The panel will initially be offered at WuXi NextCODE's newly opened U.S. laboratory and then launched across the company's other global laboratories in Shanghai and Dublin.